| abstract |
(I) identifying a patient having a PD-L1-negative melanoma; and (ii) administering to the patient an anti-PD-1 antibody or antigen-binding portion thereof and an anti-CTLA- Lt; RTI ID = 0.0 > of: < / RTI > The methods of the invention can be used to prolong progression-free survival by more than 8 months and / or to reduce tumor size by at least about 10%, about 20%, about 30%, about 40%, or about 50% . |